FILE:LIFE/LIFE-8K-20030818142731.txt.gz
EVENTS:	Other events	Financial statements and exhibits
TEXT:
ITEM: Other events
ITEM: Financial statements and exhibits
Table of Contents
Table of Contents
Item 5. OTHER EVENTS
On August 14, 2003, Invitrogen Corporation (the "Company") issued a press release regarding the closing of its offering of an additional $25 million aggregate principal amount of 2% Convertible Senior Notes due 2023 pursuant to a 13 day over-allotment option, which has now expired, to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Attached as Exhibit 99.1 is the press release of the Company regarding the additional closing of the offering of the Convertible Senior Notes. Exhibit 99.1 is incorporated by reference under this Item 5.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS.
     (c)  Exhibits.
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Table of Contents

 
Exhibit 99.1
Contact:
Paul Goodson VP Investor Relations Invitrogen Corporation (760) 603-7208
CARLSBAD, CA  August 14, 2003  Invitrogen Corporation (Nasdaq: IVGN) today announced that it has completed the private placement of an additional $25 million of 2% senior convertible notes due 2023 to qualified institutional buyers, pursuant to Rule 144A under the Securities Act of 1933, as amended.
The $25 million private placement is in addition to the private placement of $325 million completed on August 1, 2003. The current transaction represents the partial exercise by the initial purchasers of an option to purchase additional notes. The remaining portion of the option is now expired.
This announcement is neither an offer to sell nor a solicitation to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. The securities will not be registered under the Securities Act, or any state securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state laws.


